YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Biogen Applies for FDA Approval of Hemophilia Med

January 4, 2013 | Biogen Idec has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of a treatment for hemophilia B. The regulatory submission was based on results from B-LONG, the largest registrational phase 3 clinical study in hemophilia B to date. Biogen Idec Press Release 
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.